Naini Afsoon Emami, Asiabi Reza Ebrahimi Kord, Keivandarian Noushin, Moeinzadeh Firouzeh
Department of Internal Medicine, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2015 Aug 10;4:167. doi: 10.4103/2277-9175.162544. eCollection 2015.
End stage renal disease (ESRD) is a state of micro inflammation that attenuates patient's life span and quality of life. Inflammatory markers like interlukin 6 (IL-6) and C- reactive protein (CRP) can predict inflammatory state in ESRD patients. Dietary limitations are risk factors for omega-3 deficiency in these patients. Omega-3 supplementation is an attractive material that proposed in inflammation modulation. The aim of this study is evaluation of effect of omega-3 supplementation on IL-6 and CRP level in chronic ambulatory peritoneal dialysis (CAPD) patients.
This randomized controlled double-blind clinical trial is performed in 40 CAPD patients in two academic hospitals in Isfahan, Iran. One group received 1000 mg omega-3 capsule (each capsule contains 180 mg Eicosapentanoic and 120 mg Dosahexanoic acid) three times a day orally for 8 weeks (n = 20) and the other matched group by placebo (n = 20). Serum level of IL-6 and quantitative CRP (Q-CRP) were measured in beginning and the end of the study. Finally all data were analyzed by SPSS version 18.
Mean age of patients was 53 years old in omega-3 group patients and 54 years old in placebo group. There were not any differences in CRP and IL-6 level in the beginning and the end of study between two groups (P: 0.81 and 0.10 for CRP and 0.26 and 0.23 for IL-6, respectively).
Omega-3 supplementation did not effect on inflammatory markers (Q-CRP and IL-6) in CAPD patients after 8 weeks.
终末期肾病(ESRD)是一种微炎症状态,会缩短患者寿命并降低生活质量。白细胞介素6(IL-6)和C反应蛋白(CRP)等炎症标志物可预测ESRD患者的炎症状态。饮食限制是这些患者ω-3缺乏的危险因素。补充ω-3是一种在炎症调节方面被提出的有吸引力的物质。本研究的目的是评估补充ω-3对慢性非卧床腹膜透析(CAPD)患者IL-6和CRP水平的影响。
这项随机对照双盲临床试验在伊朗伊斯法罕的两家学术医院的40名CAPD患者中进行。一组患者口服1000毫克ω-3胶囊(每粒胶囊含有180毫克二十碳五烯酸和120毫克二十二碳六烯酸),每日三次,共8周(n = 20),另一组匹配的患者服用安慰剂(n = 20)。在研究开始和结束时测量血清IL-6水平和定量CRP(Q-CRP)。最后,所有数据通过SPSS 18版进行分析。
ω-3组患者的平均年龄为53岁,安慰剂组为54岁。两组在研究开始和结束时的CRP和IL-6水平均无差异(CRP分别为P:0.81和0.10,IL-6分别为0.26和0.23)。
8周后补充ω-3对CAPD患者的炎症标志物(Q-CRP和IL-6)没有影响。